Regenerative Medicine in Colorado

Tuesday, November 28, 2017


Layne Los, PhD, CEO of ClaroLabs announced the company has raised $800K in the first round of a $2M Series A preferred stock offering

Monday, November 27, 2017

Layne Los, PhD, CEO of ClaroLabs announced the company has raised $800K in the first round of a $2M Series A preferred stock offering. The company recently setup operations in a 5000+ sq. ft. facility in Lafayette, CO. Claro Scientific Laboratories, Inc is a clinical reference Lab (CLIA) providing urine drug testing services for Addiction Recovery Clinics, Pain Clinics and a Direct to Consumer service.

For people with Substance Use Disorder (SUD, diagnosed or not) knowing unequivocally if a loved one is using is one of the first steps in the recovery process. Unlike other less sophisticated tests, our service detects 152 drugs, many days if not weeks, after drug use (depending on the drug and dose). ClaroLabs will be accepting samples in January 2018.

For more information and to order a test kit, visit

Continue Reading

Ready for Retirees

Tuesday, November 14, 2017


miRagen Therapeutics to Participate in Four Investor Conferences in November

Monday, November 13, 2017

miRagen Therapeutics, Inc. (NASDAQ:MGEN) a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer, will provide a company overview at the following conferences in November. 

miRagen Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update

Monday, November 13, 2017


Former Array Biopharma COO, Dr. David L. Snitman joins AmideBio Business Advisory Board

Monday, November 13, 2017

AmideBio LLC, a privately-held biopharmaceutical company, announced today that Dr. David L. Snitman has joined its business advisory board. Dr. Snitman has extensive experience with company financing as well as building strategic alliances with the pharmaceutical industry. He will be a huge asset to the company as it develops its pipeline of novel drugs targeting diabetes and other metabolic diseases.

“We are delighted to have Dr. Snitman join the AmideBio Advisory Board as we develop our pipline of drug candidates targeting serious unmet medical needs,” said Dr. Misha Plam, President and CEO of Amide Bio.“Dr. Snitman’s knowledge of pharmaceutical drug development and financing, combined with his extensive experience in negotiating and managing strategic partnerships across the pharmaceutical industry will be immensely valuable to us.“

“I am excited to be joining AmideBio’s advisory board. The Company has an impessive pipeline of drug candidates that could significantly impact the way diabetes and congenital hyperinsulinism are treated,” said Dr. David L. Snitman. “I am impressed by the quality and novelty of research at AmideBio as well as the team driving to help patients afflicted with these treatment-challenged diseases.”

Dr. Snitman is currently a principal at DL SNITMAN LLC, a consulting firm providing business development services to the biotechnology industry. Dr. Snitman is a co-founder of Array BioPharma and served as Chief Operating Officer & Vice President, Business Development from 1998 to 2015. He was a member of Array’s Board of Directors from May 1998 to October 2012. Prior to forming Array, Dr. Snitman held senior positions with Amgen Inc. including Associate Director, New Products and Technology, and Manager of Amgen's Boulder research facility. Dr. Snitman received a B.S. in chemistry from Northeastern University and obtained a Ph.D. in the synthesis of natural products from the University of Colorado. He was an NIH Postdoctoral Fellow at the Massachusetts Institute of Technology.

Continue Reading

Colorado BioScience Association Recognizes State’s Innovators and Leaders at Annual Awards Dinner

Thursday, November 09, 2017

Array Biopharma Named Company of the Year, Cerescan Honored as Rising Star 
Continue Reading

Biodesix Oral Presentation At SITC: Testing Methodology May Identify Primary Immunotherapy Resistance In Patients

Thursday, November 09, 2017

Preliminary Data Indicate Primary Resistance May Be Overcome by Combination Therapies 
Continue Reading

ImmunoMolecular Therapeutics Launches to Advance Innovative Immuno therapi es for Genetically Defined Type 1 Diabetes and Other Autoimmune Diseases

Thursday, November 09, 2017

ImmunoMolecular Therapeutics (IM Therapeutics), a company developing personalized small molecule therapies for the treatment of genetically defined autoimmune diseases, today made its debut as a spinout from the Barbara Davis Center for Diabetes at the University of Colorado. IM Therapeutics was co-founded by Peter Gottlieb, M.D., Professor of Pediatrics and Medicine with tenure at the University of Colorado Health Science Center, and Director of Translational Research Unit at the Barbara Davis Center for Diabetes; and Aaron Michels, M.D., Associate Professor of Pediatrics & Medicine at the University of Colorado Denver, the Frieda and George S. Eisenbarth Clinical Immunology Endowed Chair, and Director of Clinical Immunology at the Barbara Davis Center for Diabetes.

IM Therapeutics was created to advance new therapeutic strategies for Type 1 Diabetes (T1D) that aim to directly inactivate pathogenic immune cells responsible for damaging the insulin-producing beta cells in the pancreas. The key to this approach is the group of immune molecules called human leukocyte antigens (HLA). Because HLA molecules arise from genes that are slightly different among individuals (i.e., alleles), some HLA alleles function in an abnormal way to “mis-present” autoantigens that leads the body to mount an immune system attack against itself. The HLA-DQ8 allele is one such gene known to predispose individuals that carry it for T1D by mis-presenting autoantigens that favor the generation and function of harmful, but not protective, immune cells.
“The strategy of directly inhibiting HLA-DQ8 has the potential to preserve beta-cell function if treatment is started early,” says Dr. Michels. “With current advancements in diagnostics, we can identify individuals with the HLA-DQ8 gene at risk of T1D before symptoms occur.”

Dr. Gottlieb continued, “Our ultimate goal is to inhibit the initiation of an autoimmune response, thus maintaining normal insulin production. I am excited to be part of a company that could potentially reduce T1D patients’ lifelong dependence on insulin.”
IM Therapeutics’ scientific co-founders discovered that an oral small molecule drug, methyldopa, targets and inhibits the HLA-DQ8 molecule. The company’s lead candidate, IMT-002, is a proprietary formulation of the D enantiomer of methyldopa. The D enantiomer offers more convenient dosing, better potency and less side effects than the L enantiomer which is an anti-hypertensive. The company has received orphan designation for methyldopa, which applies to both enantiomers. IMT-002 is currently in preclinical development as a candidate to treat T1D in patients with the HLA-DQ8 gene. Drs. Gottlieb and Michels will continue to advance the development of autoimmune therapies for IM

Therapeutics as Chief Medical Officer and Chief Scientific Officer, respectively, while maintaining their clinical and academic appointments.

“Our unique personalized small molecule approach to immunotherapy utilized in IMT-002, is being developed to block the peptide binding groove of DQ8 on specific white blood cells,” said Steve Orndorff, Ph.D., President and Chief Executive Officer, IM Therapeutics. “If successful, the pathogenic immune cells would not be able to identify the pancreatic beta-cells and the immune system can’t attack what it can’t see. While our initial focus is on T1D, our intent is to pursue this approach with other genetically defined autoimmune diseases, such as celiac disease.”

The company will be led by Dr. Orndorff as President and Chief Executive Officer and Greg Kading, CFA as Chief Financial Officer and Chief Operating Officer. Dr. Orndorff and Mr. Kading previously worked together at Accera, where they were instrumental in guiding the company from R&D to commercialization.

IM Therapeutics also announced the appointment of a Clinical Advisory Board. Clinical Advisors include renowned researchers in diabetes and immunotherapy, Mark Atkinson, Ph.D., Jay Skyler, M.D., MACP, Stephen Gitelman, M.D., Howard L. Weiner, M.D. and V. Michael Holers, M.D.

Continue Reading

Colorado BioScience Association to Honor Life Science Industry Innovation, Leadership at 2017 Awards Dinner

Wednesday, November 08, 2017

Colorado BioScience Association highlights a banner year marked by acquisitions, investments, discoveries and partnerships during its 14th Annual Awards Dinner on Thursday, November 9 in downtown Denver at the Hyatt Regency. The event celebrates the companies, organizations and individuals who contribute to Colorado’s national reputation for innovation in life science.